110 related articles for article (PubMed ID: 6368760)
21. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
22. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
Lotz JP; Machover D; Malassagne B; Hingh B; Donsimoni R; Gumus Y; Gerota J; Lam Y; Tulliez M; Marsiglia H
J Clin Oncol; 1991 Oct; 9(10):1860-70. PubMed ID: 1919636
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
24. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors.
Cooper MA; Einhorn LH
J Clin Oncol; 1995 May; 13(5):1167-9. PubMed ID: 7738621
[TBL] [Abstract][Full Text] [Related]
25. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.
Nichols CR; Andersen J; Lazarus HM; Fisher H; Greer J; Stadtmauer EA; Loehrer PJ; Trump DL
J Clin Oncol; 1992 Apr; 10(4):558-63. PubMed ID: 1312584
[TBL] [Abstract][Full Text] [Related]
26. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH
Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of VP-16-213 in non-small-cell lung cancer.
Itri LM; Gralla RJ; Chapman RA; Kelsen DP; Casper ES; Golbey RB
Am J Clin Oncol; 1982 Feb; 5(1):45-7. PubMed ID: 7081137
[TBL] [Abstract][Full Text] [Related]
29. [Phase I study of an oral administration of VP 16-213].
Ogawa M; Ota K; Oyama A; Fukuoka M; Takada M; Yoshida S; Sanpi K; Kimura I; Ohnoshi T; Kuraishi Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2403-7. PubMed ID: 6639102
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH
Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
34. VP-16-213. A phase II trial using a weekly schedule.
Karp G; Antman K; Canellos G
Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129
[TBL] [Abstract][Full Text] [Related]
35. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
37. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
38. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors.
Droz JP; Pico JL; Ghosn M; Kramar A; Rey A; Ostronoff M; Baume D
Bull Cancer; 1992; 79(5):497-507. PubMed ID: 1421710
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
[TBL] [Abstract][Full Text] [Related]
40. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]